CytomX Therapeutics Inc (NASDAQ: CTMX) kicked off on Friday, down -3.47% from the previous trading day, before settling in for the closing price of $1.73. Over the past 52 weeks, CTMX has traded in a range of $1.04-$2.86.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 28.25%. While this was happening, its average annual earnings per share was recorded -3067.00%. With a float of $66.42 million, this company’s outstanding shares have now reached $67.31 million.
Considering the fact that the conglomerate employs 122 people, you should pay attention to its efficiency factor.
CytomX Therapeutics Inc (CTMX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of CytomX Therapeutics Inc is 1.92%, while institutional ownership is 48.26%. The most recent insider transaction that took place on Mar 19 ’24, was worth 42,175. In this transaction CEO of this company sold 20,223 shares at a rate of $2.09, taking the stock ownership to the 524,481 shares. Before that another transaction happened on Mar 19 ’24, when Company’s SVP, Chief Scientific Officer sold 12,795 for $2.09, making the entire transaction worth $26,684. This insider now owns 168,579 shares in total.
CytomX Therapeutics Inc (CTMX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 40.48 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3067.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.90% during the next five years compared to 67.21% growth over the previous five years of trading.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
Take a look at CytomX Therapeutics Inc’s (CTMX) current performance indicators. Last quarter, stock had a quick ratio of 1.17. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.12.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.02, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.37 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
Compared to the last year’s volume of 0.86 million, its volume of 0.4 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 6.83%. Additionally, its Average True Range was 0.14.
During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 22.80%, which indicates a significant increase from 5.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.28% in the past 14 days, which was lower than the 79.52% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0282, while its 200-day Moving Average is $1.6053. Nevertheless, the first resistance level for the watch stands at $1.7350 in the near term. At $1.8000, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.8500. If the price goes on to break the first support level at $1.6200, it is likely to go to the next support level at $1.5700. Now, if the price goes above the second support level, the third support stands at $1.5050.
CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats
The company with the Market Capitalisation of 113.09 million has total of 67,732K Shares Outstanding. Its annual sales at the moment are 101,210 K in contrast with the sum of -570 K annual income. Company’s last quarter sales were recorded 26,610 K and last quarter income was 840 K.
